Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

NCT03015792 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Drug company decided to not fund the phase 2 portion

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

DRUG: Dexamethasone
DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide
OTHER: Pharmacological Study
OTHER: Quality-of-Life Assessment

Sponsor

Mayo Clinic